Comparison of HercepTestTM mAb pharmDx (Dako Omnis, GE001) with Ventana PATHWAY anti-HER-2/neu (4B5) in breast cancer: correlation with HER2 amplification and HER2 low status. Here, ERBB2 is linked to breast carcinoma.